Vericel (VCEL) EPS (Basic) (2010 - 2026)

Vericel (VCEL) posted EPS (Basic) of $0.03 for Q2 2026, up 125.63% sequentially from -$0.13 in Q1 2026, and up 274.38% YoY from $0.01 in Q2 2025.

Analysis

Vericel (VCEL) EPS (Basic) (2010 - 2026) Analysis & Trends

Vericel has reported EPS (Basic) for 17 years, with the latest figure at $0.03 in Q2 2026.

Quarterly EPS (Basic) rose 274.38% year-over-year to $0.03 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $0.45 (up 266.08% YoY) and the FY2025 annual result came in at $0.33, up 54.68% from the prior year.
EPS (Basic) climbed to $0.03 in Q2 2026 per VCEL's latest filing, from -$0.13 in the prior quarter.
Over five years, EPS (Basic) peaked at $0.46 in Q4 2025 and troughed at -$3.46 in Q2 2023.
A 5-year average of -$0.19 and a median of -$0.08 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2023 and 2025: EPS (Basic) slumped 1716.79% in 2023, then surged 599.91% in 2025.
Over 5 years, EPS (Basic) stood at $0.13 in 2022, then jumped by 117.28% to $0.27 in 2023, then soared by 48.52% to $0.41 in 2024, then advanced by 13.99% to $0.46 in 2025, then sank by 92.53% to $0.03 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered $0.03, -$0.13, and $0.46 for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	12.62
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	7.70
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-1.96
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-3.06
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	2.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	1.23
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.18
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.06
10	Vericel	2.05 Bn	1.89 Bn	56.40 Mn	0.04

Historic Data

Download Data